A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of veliparib
(ABT-888)and to establish the recommended Phase 2 dose of veliparib (ABT-888) when
administered in combination with carboplatin and gemcitabine in subjects with advanced solid
tumors.